SCHEMBL17607113

SCHEMBL17607113

O=C(Nc1cnn(CCO)c1)c1cc(C(=O)c2c(Cl)ccc(Cl)c2F)c[nH]1

nearest known ligand 0.75

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAPK7 Q13164 20/20 0.75
AURKA O14965 1/20 0.75
DCLK1 O15075 1/20 0.75
ABL1 P00519 1/20 0.75
CSF1R P07333 1/20 0.75
KIT P10721 1/20 0.75
FGFR1 P11362 1/20 0.75
JAK3 P52333 1/20 0.75
MAP2K5 Q13163 1/20 0.75
LRRK2 Q5S007 1/20 0.75
KCNH2 Q12809 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17607200 0.90 MAPK7 (0.75) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL17607241 0.89 MAPK7 (0.77) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL17607149 0.88 MAPK7 (0.72) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL17607267 0.87 MAPK7 (0.71) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL17607190 0.86 MAPK7 (1.00) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL20265813 0.86 MAPK7 (0.69) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL20265938 0.85 MAPK7 (0.54) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL17607195 0.84 MAPK7 (0.66) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL20265914 0.83 MAPK7 (0.68) MAPK7AURKADCLK1ABL1CSF1R
SCHEMBL17607087 0.83 MAPK7 (1.00) MAPK7AURKADCLK1ABL1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344017-B2 Pyrrolcarboxamide derivatives for the inhibition of ERK5 CANCER RESEARCH TECH LTD (GB) 2019-07-09 US claimed
US-20180170911-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-06-21 US claimed
EP-3194390-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 Cancer Research Technology Ltd (GB) 2017-07-26 EP claimed
WO-2016042341-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-03-24 WO claimed
US-10344017-B2 Pyrrolcarboxamide derivatives for the inhibition of ERK5 CANCER RESEARCH TECH LTD (GB) 2019-07-09 US disclosed
US-10344017-B2 Pyrrolcarboxamide derivatives for the inhibition of ERK5 CANCER RESEARCH TECH LTD (GB) 2019-07-09 US disclosed
US-20180170911-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-06-21 US disclosed
US-20180170911-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-06-21 US disclosed
EP-3194390-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 Cancer Research Technology Ltd (GB) 2017-07-26 EP disclosed
WO-2016042341-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170911-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 MAPKAPK5, MAP3K5, MAPK15 MAPK7 38/4885AURKA 2742/4885DCLK1 2762/4885
US-10344017-B2 Pyrrolcarboxamide derivatives for the inhibition of ERK5 MAPKAPK5, MAP3K5, MAPK15 MAPK7 38/4885AURKA 2742/4885DCLK1 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.